Lorena Lupinacci

B, Argentina

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Real-World Outcomes in Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer in Argentina: A Multicenter Retrospective Study (GAOT-ALK001).

Real-World Outcomes in Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer in Argentina: A Multicenter Retrospective Study (GAOT-ALK001).

Journal: JCO global oncology

Published: October 03, 2025

Validation of the Lung Immune Prognostic Index in patients with untreated advanced non-small cell lung cancer: Post hoc analysis of the IMpower 130, 131 and 150 trials.

Validation of the Lung Immune Prognostic Index in patients with untreated advanced non-small cell lung cancer: Post hoc analysis of the IMpower 130, 131 and 150 trials.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: September 26, 2024

The FLARE Score and Circulating Neutrophils in Patients with Cancer and COVID-19 Disease.

The FLARE Score and Circulating Neutrophils in Patients with Cancer and COVID-19 Disease.

Journal: Cancers

Published: July 12, 2024

Efficacy of First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma: A Multicenter Real-World Study (ImmunoMeso LATAM).

Efficacy of First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma: A Multicenter Real-World Study (ImmunoMeso LATAM).

Journal: Clinical lung cancer

Published: June 29, 2024

Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.

Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.

Journal: Journal for immunotherapy of cancer

Published: June 14, 2024

Prevalence and clinical factors associated with survival in patients with EGFR-mutated lung cancer in Argentina.

Prevalence and clinical factors associated with survival in patients with EGFR-mutated lung cancer in Argentina.

Journal: Ecancermedicalscience

Published: April 02, 2024

Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.

Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.

Journal: Clinical lung cancer

Published: August 22, 2023

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 12, 2022

Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations.

Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 13, 2022

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: June 30, 2021

Outcomes of patients with non-small cell lung cancer and poor performance status treated with immune checkpoint inhibitors in the real-world setting.

Outcomes of patients with non-small cell lung cancer and poor performance status treated with immune checkpoint inhibitors in the real-world setting.

Journal: International journal of clinical oncology

Published: September 20, 2020

Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP).

Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP).

Journal: Thoracic cancer

Published: October 02, 2019

Showing 1-12 of 15

Last Updated: 09/26/2026